Nitric oxide and murine coxsackievirus B3 myocarditis: aggravation of myocarditis by inhibition of nitric oxide synthase

Second Department of Internal Medicine, Toyama Medical and Pharmaceutical University, Japan.

OBJECTIVES: This study sought to investigate the effects of nitric oxide inhibition in a murine model of coxsackievirus B3 myocarditis. BACKGROUND: Little is known about the contribution of nitric oxide to the pathophysiology of myocarditis. METHODS: Antiviral activity was tested in vitro using nitric oxide inhibition by treatment with activated macrophages of NG-nitro-L-arginine methyl ester. In the in vivo experiments, NG-nitro-L-arginine methyl ester and NG-nitro-D-arginine methyl ester (both at 100 micrograms/ml) were administered to C3H/He mice early (days 0 to 14) and late (days 14 to 35) after infection with coxsackievirus B3. RESULTS: In the in vitro experiments with interferon-gamma- and lipopolysaccharide-induced activated murine macrophages, treatment with the nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester, but not its inactive enantiomer NG-nitro-D-arginine methyl ester, restored coxsackievirus B3 titers. In the in vivo experiments in the early treatment group, myocardial virus titers were higher in NG-nitro-L-arginine methyl ester-treated than infected untreated animals, and both inflammatory cell infiltration and necrosis were more severe. In the late treatment group, more severe necrosis and more dense myocardial and perivascular fibrosis were observed in NG-nitro-L-arginine methyl ester-treated than in infected untreated animals. NG-Nitro-D-arginine methyl ester administration was ineffective. CONCLUSIONS: Nitric oxide inhibition increases myocardial virus titers, resulting in the aggravation of cardiac pathology in the early stage of coxsackievirus B3 myocarditis. In the late stage, it induces more severe cardiomyopathic lesions. Nitric oxide plays a defensive role in the pathogenesis of coxsackievirus B3 myocarditis.

This article has been cited by other articles:

				T.-a. Okabe, K. Shimada, M. Hattori, T. Murayama, M. Yokode, T. Kita, and C. Kishimoto Swimming reduces the severity of atherosclerosis in apolipoprotein E deficient mice by antioxidant effects Cardiovasc Res, June 1, 2007; 74(3): 537 - 545. [Abstract] [Full Text] [PDF]

				F. Benencia, M. C. Courreges, G. Gamba, H. Cavalieri, and E. J. Massouh Effect of Aminoguanidine, a Nitric Oxide Synthase Inhibitor, on Ocular Infection with Herpes Simplex Virus in Balb/c Mice Invest. Ophthalmol. Vis. Sci., May 1, 2001; 42(6): 1277 - 1284. [Abstract] [Full Text]

				A. M Shah Inducible nitric oxide synthase and cardiovascular disease Cardiovasc Res, January 1, 2000; 45(1): 148 - 155. [Full Text] [PDF]

				C. Zaragoza, C. J. Ocampo, M. Saura, C. Bao, M. Leppo, A. Lafond-Walker, D. R. Thiemann, R. Hruban, and C. J. Lowenstein Inducible Nitric Oxide Synthase Protection Against Coxsackievirus Pancreatitis J. Immunol., November 15, 1999; 163(10): 5497 - 5504. [Abstract] [Full Text] [PDF]

				A. Iwasaki, A. Matsumori, T. Yamada, T. Shioi, W. Wang, K. Ono, R. Nishio, M. Okada, and S. Sasayama Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis J. Am. Coll. Cardiol., April 1, 1999; 33(5): 1400 - 1407. [Abstract] [Full Text] [PDF]

				C. Zaragoza, C. Ocampo, M. Saura, M. Leppo, X.-Q. Wei, R. Quick, S. Moncada, F. Y. Liew, and C. J. Lowenstein The role of inducible nitric oxide synthase in the host response to Coxsackievirus myocarditis PNAS, March 3, 1998; 95(5): 2469 - 2474. [Abstract] [Full Text] [PDF]

				W. J. Paulus, S. Kastner, P. Pujadas, A. M. Shah, H. Drexler, and M. Vanderheyden Left Ventricular Contractile Effects of Inducible Nitric Oxide Synthase in the Human Allograft Circulation, November 18, 1997; 96(10): 3436 - 3442. [Abstract] [Full Text]